The FDA approved a pill version of the GLP-1 receptor agonist semaglutide (Wegovy), making it the first oral GLP-1 agent ...

CINCINNATI (WKRC) - The surge in popularity of weight loss drugs like Ozempic and Trulicity has led to a rise in counterfeit versions, according to customs agents at Cincinnati/Northern Kentucky ...

Weight-loss drugs promise to make the pounds melt away, and beauty products and fillers will erase those fine lines. But do you know what you're getting or where it's coming from? WLWT News Five ...

The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva Pharmaceuticals announced Thursday. The generic form of liraglutide (Saxenda) is ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The seized items, valued at over $400K include contact lenses, weight loss drugs, Botox, dermal fillers, and skin care ...

With many consumers turning to Ozempic and other glucagon-like peptide receptor agonists (GLP-1RAs) for weight loss, a new study is looking at the ways these drugs have other health benefits.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Dapiglutide was linked to weight loss at 13 weeks at ...

California recently passed a budget for 2025-2026 that eliminates Medicaid coverage for GLP-1 agonists for weight loss. Other states are considering similar cuts. States are struggling to close gaps ...

Patients frequently come to Leslie Golden, MD, with questions about supplements for weight loss. “I’d say nearly every patient has tried or considered supplements at some point before they get to me — ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized ...